MedTrace Logo

Non-Inferiority Comparison of Migrane® Versus Parcel ® For Treatment of Tensional Cephaleia

NCT01408069 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different associations of drugs in the treatment of patients diagnosed with tensional-type headache in accordance with International Headache Society guidelines.

Conditions

  • Tensional-type Headache

Interventions

DRUG

MIGRANE

1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)

DRUG

PARCEL

1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408069 on ClinicalTrials.gov